<DOC>
	<DOCNO>NCT01367210</DOCNO>
	<brief_summary>Objectives study : 1 . To verify safety efficacy study treatment , define persistent control virus ' replication 48 week simplification maraviroc + darunavir ritonavir patient R5 tropism viral DNA genotyping . 2 . To collect relevant information safety , immunologic economic impact strategy .</brief_summary>
	<brief_title>Switch Darunavir/r + Maraviroc Quaque Die Patients With R5 Tropism Viral DNA Genotyping ( GUSTA )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Patients treat regimen include 3 HAART least 4 month Aged 18 year old Who give inform consent participation study With least two viral load &lt; 50 copies/mL two consecutive determination least 6 month apart ( tolerance two week ) With CD4 cell count &gt; 200 cells/Î¼L absence opportunistic infection AIDSrelated disease least one year prior screen . With R5 tropism viral DNA genotyping ( geno2pheno `` clonal '' ) With CD4 cell count nadir &gt; 50 cell/mmc 100 cell/mmc previous enfuvirtide integrase inhibitor use With least one major two minor mutation confer resistance darunavir report update list International AIDS Society USA , previous resistance test Previous D/M X4 viral tropism Previous major clinical toxicity ( grade &gt; =3 ) propose drug study Pregnancy breast feeding , desire pregnancy short term Past exposure Chemokine Receptor 5 antagonist HBsAg serostatus Liver cirrhosis class C ( ChildPugh ) Sulpha drug hypersensitivity The presence major non AIDSdefining disease , opinion investigator , may compromise retention patient study necessary followup period . Estimated glomerular filtration &lt; 30 ml/min ( cockroftGaut ; MDRD formula blackAfrican africanamerican ) screen visit Hypertransaminasemia grade IV ( 10 time upper normal limit ) screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Highly Active AntiRetroviral Therapy</keyword>
	<keyword>Simplification</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Treatment experience</keyword>
	<keyword>Tropism</keyword>
</DOC>